PDE4A and psoriasis: The broad anti‐inflammatory effect seen in psoriasis patients after treatment with orismilast is in alignment with preclinical data of orismilast in vitro and in vivo [10] and supports the mechanistic hypothesis of PDE4 inhibition impacting T cell receptor activation through the cAMP signalling pathway and keratinocyte activation, as reviewed by Pincelli et al.